文献速递神经肿瘤

PCV单药化疗可延长WHO 2级少突胶质细胞瘤疾病控制并降低恶性进展风险

PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
PubMed 文献 · J Neurooncol · 2021-05-01

该研究纳入142例分子定义的WHO 2级少突胶质细胞瘤患者,分为活检后观察等待、仅手术切除、活检后TMZ化疗和活检后PCV化疗四组。结果显示PCV组无进展生存期最长(9.1年),10年内组织学进展至3级比例最低(9%),PCV单药化疗有效且恶性进展风险低。

要点

  • PCV组中位PFS为9.1年,优于观察等待(5.1年)、仅手术(4.4年)和TMZ(3.6年)。
  • PCV组10年内组织学进展至3级比例为9%,显著低于其他组。
  • 观察等待组首次复发时接受PCV者PFS优于TMZ(7.2 vs 4.0年)。

核心结论

  • PCV单药化疗对WHO 2级少突胶质细胞瘤有效,可延长无进展生存期并降低组织学恶性进展风险。

研究设计与样本

  • 回顾性分析142例分子定义的WHO 2016版2级少突胶质细胞瘤患者,分为观察等待(n=59)、仅手术切除(n=27)、活检后TMZ(n=26)和活检后PCV(n=30)四组。

主要发现

  • PCV组PFS为9.1年,观察等待组5.1年,仅手术组4.4年,TMZ组3.6年。
  • 10年内组织学进展至3级比例:PCV组9%,观察等待组29%,仅手术组67%,TMZ组75%(p=0.01)。
  • 观察等待组首次复发时PCV治疗者较TMZ治疗者PFS更长(7.2 vs 4.0年,p=0.04)。
  • 多因素分析显示干预前肿瘤体积较小与PFS预后相关(p=0.02)。

关键数值与推荐

  • PCV组10年内组织学进展至3级比例为9%,观察等待组29%,仅手术组67%,TMZ组75%(p=0.01)。
  • 观察等待组复发后PCV vs TMZ的PFS分别为7.2年和4.0年(p=0.04)。

临床怎么用

  • 对于活检后新诊断的WHO 2级少突胶质细胞瘤,PCV单药化疗可作为有效治疗选择,尤其适合希望延迟放疗或减少恶性进展风险的患者。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of chemotherapy alone in newly diagnosed WHO grade 2 oligodendroglioma after biopsy, incomplete or gross total resection remains controversial. We here analyze the clinical outcome of four patient cohorts being treated with either procarbazine, CCNU and vincristine (PCV) or temozolomide (TMZ) after biopsy, resection only, or wait-and-scan after biopsy. METHODS: Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy. Presurgical MRI T2 tumor volumes were obtained by manual segmentation. Progression-free survival (PFS), post-recurrence PFS (PR-PFS) and rate of histological progression to grade 3 were analyzed. RESULTS: PFS was longest after PCV (9.1 years), compared to 5.1 years after W&S, 4.4 years after RES and 3.6 years after TMZ. The rate of histological progression from grade 2 to 3 within 10 years was 9% for the PCV, 29% for the W&S, 67% for the RES and 75% for the TMZ group (p = 0.01). In the W&S group, patients treated with PCV at first relapse had a longer PFS from intervention than those treated with TMZ (7.2 vs 4.0 years, p = 0.04). Multivariate analysis identified smaller tumor volume prior to any intervention (p = 0.02) to be prognostic for PFS. CONCLUSIONS: PCV chemotherapy alone is an effective treatment for WHO grade 2 oligodendroglioma, with long PFS and low rate of histological progression.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Weller J, Katzendobler S, Karschnia P, et al. PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. J Neurooncol. 2021. PMID: 33932195. doi:10.1007/s11060-021-03765-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。